Vaccine Manufacture and Supply – News and Features

The lack of equitable access to COVID-19 vaccines undercuts the ethical basis for vaccination “passports” to confer eligibility for domestic and international travel, according to an analysis published in the Journal of Medical Ethics.

Learn how a freezer inventory management software enables biobanks to seamlessly manage & track storage locations of vaccines, ensure effective cold chain management, assuring quality and safe distribution of COVID-19 vaccines.

Science writer Anthony King takes a close look at how each of the authorized COVID-19 vaccines are made, and the challenges faced when working to vaccinate the global population.

Research on the ChAdOx1 nCoV-19, also known as the Oxford-AstraZeneca vaccine, indicates that a long interval between first and second doses does not compromise the immune response after a late second dose, and a third dose of the vaccine continues to boost antibodies against SARS-CoV-2.

A new vaccine to protect against deadly cholera has been made by grinding up genetically modified grains of rice. The first human trial has shown no obvious side effects and a good immune response.

The biotechnology company CureVac has announced that its Phase IIb/III clinical trial of the COVID-19 vaccine candidate CVnCoV demonstrates an interim efficacy of 47%.

The biotechnology company Novavax has announced that its Phase III clinical trial of the COVID-19 vaccine NVX-CoV2373 demonstrated an overall efficacy of 90.4%.

In this article, Keir Lewis explores how antibody testing can help provide invaluable data that can be used to inform the next stage of the vaccination program rollout.

David Elder explores the risk–benefit profiles for various COVID-19 vaccines and discusses the steps taken by regulatory agencies in response to the occurrence of rare blood clotting events associated with the Oxford–AstraZeneca vaccine.

The UK Medicines and Healthcare Regulatory Agency (MHRA) has authorized an extension to the UK approval of the Pfizer/BioNTech COVID-19 vaccine (BNT162b2), permitting its use in children aged 12–15.